English | 繁體

Search in the results

UM

Browse/Search Results:  1-3 of 3 Help

Selected(0)Clear Items/Page:    Sort:
Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation Journal article
Zhou,Jing Bo, Tang,Dongyang, He,Lin, Lin,Shiqi, Lei,Josh Haipeng, Sun,Heng, Xu,Xiaoling, Deng,Chu Xia. Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation[J]. Pharmacological Research, 2023, 194, 106830.
Authors:  Zhou,Jing Bo;  Tang,Dongyang;  He,Lin;  Lin,Shiqi;  Lei,Josh Haipeng; et al.
Favorite | TC[WOS]:6 TC[Scopus]:6  IF:9.1/9.0 | Submit date：2023/08/03
Bortezomib (Pubchem Cid: 387447)  Cepharanthine (Pubchem Cid: 10206)  Docetaxel (Taxotere) (Pubchem Cid: 11970251)  Drug Combination Therapy  Flunarizine Dihydrochloride (Pubchem Cid: 5282407)  Lapatinib Ditosylate (Pubchem Cid: 9941095)  Machine Learning  Pazopanib Hydrochloride (Pubchem Cid: 11525740)  Potential Combination Biomarkers  Tamoxifen Citrate (Pubchem Cid: 2733525)  Three-dimensional Tumor Slice Culture  Vatalanib (Pubchem Cid: 151194)  Vincristine (Pubchem Cid: 5978)  Xl-184 (Cabozantinib) (Pubchem Cid: 25102847)  
TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells’ killing Journal article
Xuejia Feng, Gui Yang, Litian Zhang, Shishi Tao, Joong Sup SHIM, Liang Chen, Qingxia Wu. TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells’ killing[J]. INVESTIGATIONAL NEW DRUGS, 2022, 40(6), 1244-1253.
Authors:  Xuejia Feng;  Gui Yang;  Litian Zhang;  Shishi Tao;  Joong Sup SHIM; et al.
Favorite | TC[WOS]:3 TC[Scopus]:3  IF:3.0/2.9 | Submit date：2023/01/30
Trim59  Er-stress  Unfolded Protein Response  Er-associated Degradation  Bortezomib  Colorectal Cancer  
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells Journal article
Jiang, Xiao-Ming, Xu, Yu-Lian, Huang, Mu-Yang, Zhang, Le-Le, Su, Min-Xia, Chen, Xiuping, Lu, Jin-Jian. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells[J]. ACTA PHARMACOLOGICA SINICA, 2017, 38(11), 1512-1520.
Authors:  Jiang, Xiao-Ming;  Xu, Yu-Lian;  Huang, Mu-Yang;  Zhang, Le-Le;  Su, Min-Xia; et al.
Favorite | TC[WOS]:58 TC[Scopus]:60  IF:6.9/7.6 | Submit date：2018/10/30
Non-small Cell Lung Cancer  Egfr  Osimertinib  Pd-l1  Ubiquitin-proteasome System  Mg-132  Bortezomib  Gsk3 Beta  Licl